Market Intelligence, Clinical Progress, and High-Purity Reagents for Neurological and Oncology Drug Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for KCNG3 drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | KCNG3 Recombinant Fragment Protein High purity (>95%), Endotoxin controlled. Sequence Verified for immunization and binding assays. |
View KCNG3 Products |
| Gene Delivery | KCNG3 Promise-ORF / Lentivirus Full-length ORF for stable cell line generation. Essential for preserving native 6-transmembrane conformation. |
View KCNG3 Products |
| Benchmark Ab | Anti-KCNG3 Benchmark Antibody Recombinant positive control for surface expression validation. |
View KCNG3 Products |
| Validator | KCNG3 siRNA Set For target knockdown verification in functional assays. |
View KCNG3 Products |
| Related Target A | KCNB1 Functional binding partner (Kv2.1). KCNG3 forms heterotetramers with KCNB1 to modulate channel gating. |
View KCNB1 Products |
| Related Target B | KCNB2 Functional partner (Kv2.2). Crucial for selectivity and counter-screening in neuro-therapeutics. |
View KCNB2 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Conformational preservation of 6-transmembrane domains | High-titer Lentiviral Particles optimized for stable host membrane integration and native folding |
| Heterotetramerization verification (KCNG3/KCNB1 co-expression) | Dual-selection marker ORF vectors and sequence-verified co-transfection systems |
| Lack of Controls | Recombinant Benchmark Antibodies available for flow cytometry and binding controls |
| False Positives | Sequence-verified siRNA sets included for target-specific knockdown validation |
Live KCNG3 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The therapeutic exploration of KCNG3 (Kv6.3) is expanding, with research shifting from basic channel biophysics to targeted modulation in neurological disorders and oncology. As a modulatory (electrically silent) subunit, KCNG3 does not form functional homotetramers; instead, it heteromultimerizes with Kv2 channels. This unique regulatory mechanism makes it a highly specific target for next-generation drug discovery, aiming to bypass the systemic side effects associated with broad-spectrum potassium channel blockers.
The next wave of R&D focuses on discovering small-molecule allosteric modulators and highly selective antibodies that target the extracellular loops of the KCNG3/KCNB1 complex to treat schizophrenia, neuropathic pain, and chemoresistant cancers.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule Modulators | Academic Institutes, Specialty Neuro-Pharma | Schizophrenia, Neuropathic Pain | Cell-based functional assays (Need KCNG3/KCNB1 co-expressing stable cell lines via Lentivirus) |
| Monoclonal Antibodies | Biotech Startups | Oncology (Solid Tumors) | Extracellular loop binding assays (Need sequence-verified antigens and benchmark controls) |
| RNA Therapeutics | Gene Therapy Pioneers | Channelopathies, Epilepsy | Knockdown validation (Need high-specificity siRNA sets) |